Results presented at the 2026 ASCO Annual Meeting describe the clinical activity and preclinical basis of panitumumab-based EGFR blockade in SMARCB1-deficient renal medullary carcinoma (RMC), a collaborative multi-institutional study grounded in the discovery that RMC depends on wild-type EGFR — overexpressed without activating EGFR or RAS-pathway mutations and driven by enhancer-level epigenetic activation — rendering it susceptible to extracellular antibody blockade rather than the kinase inhibitors used against mutant-EGFR cancers. In RMC patient- and cell-derived xenografts, the anti-EGFR monoclonal antibody panitumumab produced profound regressions and outperformed the EGFR tyrosine kinase inhibitor erlotinib, providing the rationale for prospective clinical testing. Across 26 heavily pretreated patients (median 2 prior lines, 96% prior platinum, 89% stage IV at diagnosis) treated in a prospective multi-national registry between 2022 and 2025, panitumumab-based therapy achieved an objective response rate of 53.9% (14/26), including 4 complete responses (15.4%) and 10 partial responses, with a median best change in tumor size of −30.9%; toxicity was favorable, dominated by grade 1–2 acneiform rash (80.8%) with no grade 3+ rash and no treatment-related deaths. These findings support panitumumab combined with nab-paclitaxel as a new standard-of-care option for RMC — while acknowledging that the single-arm design cannot fully separate the contributions of panitumumab and chemotherapy — with ongoing work focused on mechanisms of resistance, including phenotypic transformation, tumor heterogeneity, microenvironmental ligand upregulation, and bypass pathway activation.